Table 1 Baseline and clinical characteristics of cancer patients.

From: High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy

Option

Total n = 667 (%)

NB N = 82 (12.3%)

ALL N = 202 (30.3%)

AML N = 82 (12.3%)

Solid tumor N = 147 (22%)

SCT N = 154 (23.1%)

p-value

Age

 < 10 years

295 (44.2%)

66 (80.5%)

88 (43.6%)

37 (45.1%)

50 (34.0%)

54 (35.1%)

 < 0.001

 > 10 years

372 (55.8%)

16 (19.5%)

114 (56.4%)

45 (54.9%)

97 (66.0%)

100 (64.9%)

Gender

 Male

365 (54.7%)

50 (61.0%)

92 (45.5%)

51 (62.2%)

81 (55.1%)

91 (59.1%)

0.024

 Female

302 (45.3%)

32 (39.0%)

110 (54.5%)

31 (37.8%)

66 (44.9%)

63 (40.9%)

Ethnicity

 Unknown

29 (4.3%)

0 (0.0%)

0 (0.0%)

12 (14.6%)

6 (4.1%)

11 (7.1%)

 < 0.001

 Non-Hispanic

492 (73.8%)

64 (78.0%)

151 (74.8%)

52 (63.4%)

117 (79.6%)

108 (70.1%)

 Hispanic

146 (21.9%)

18 (22.0%)

51 (25.2%)

18 (22.0%)

24 (16.3%)

35 (22.7%)

Chemotherapy within the last 2 weeks

481 (72.1%)

71 (86.6%)

148 (73.3%)

52 (63.4%)

117 (79.6%)

93 (60.4%)

 < 0.001

Fever > 39 °C

172 (25.8%)

27 (32.9%)

48 (23.8%)

24 (29.3%)

29 (19.7%)

44 (28.6%)

0.16

GI associated symptoms

230 (34.5%)

42 (51.2%)

72 (35.6%)

21 (25.6%)

62 (42.2%)

33 (21.4%)

 < 0.001

Mucositis

178 (26.7%)

39 (47.6%)

37 (18.3%)

47 (32.0%)

15 (18.3%)

40 (26%)

 < 0.001

URI

205 (30.7%)

27 (32.9%)

78 (38.6%)

16 (19.5%)

53 (36.1%)

31 (20.1%)

 < 0.001

Chills

38 (5.7%)

5 (6.1%)

12 (5.9%)

7 (8.5%)

5 (3.4%)

9 (5.8%)

0.605

Platelet < 50

418 (62.7%)

57 (69.5%)

105 (52%)

64 (78.0%)

87 (59.2%)

105 (68.2%)

 < 0.001

History BSI

200 (30%)

16 (19.5%)

53 (26.2%)

40 (48.8%)

28 (19%)

63 (40.9%)

 < 0.001

Low BP

103 (15.4%)

29 (35.4%)

21 (10.4%)

17 (20.7%)

14 (9.5%)

22 (14.3%)

 < 0.001

RVP positive

 Negative

378 (56.7%)

42 (51.2%)

115 (56.9%)

49 (59.8%)

84 (57.1%)

88 (57.1%)

0.055

 Positive

127 (19.0%)

12 (14.6%)

49 (24.3%)

8 (9.8%)

29 (19.7%)

29 (18.8%)

 Unknown

162 (24.3%)

28 (34.1%)

38 (18.8%)

25 (30.5%)

34 (23.1%)

37 (24.0%)

ANC

 < 100

466 (69.9%)

64 (78.0%)

123 (60.9%)

64 (78.0%)

117 (79.6%)

98 (63.6%)

 < 0.001

 > 100

201 (30.1%)

18 (22.0%)

79 (39.1%)

18 (22.0%)

30 (20.4%)

56 (36.4%)

AMC

 < 100

497 (76.1%)

69 (85.2%)

148 (75.5%)

68 (86.1%)

110 (75.9%)

102 (67.1%)

0.005

 > 100

156 (23.9%)

12 (14.8%)

48 (24.5%)

11 (13.9%)

35 (24.1%)

50 (32.9%)

ALC

 < 100

252 (38.3%)

41 (50.6%)

45 (22.6%)

31 (38.3%)

45 (31.0%)

90 (59.2%)

 < 0.001

 > 100

406 (61.7%)

40 (49.4%)

154 (77.4%)

50 (61.7%)

100 (69.0%)

62 (40.8%)

  1. NB neuroblastoma, ALL acute lymphoblastic leukemia, AML acute myelogenous leukemia, SCT stem cell transplant, GI gastrointestinal, URI upper respiratory tract infection, BSI bloodstream infection, BP blood pressure, RVP respiratory virus panel, ANC absolute neutrophil count, AMC absolute monocyte count, ALC absolute lymphocyte count.
Back to article page